Objective: The aim of this paper is to assess the risk/benefit ratio of clozapine in the elderly.
Method: MedLine and Internet searches, followed by cross-checking for further articles, identified the references. Reports on efficacy as well as side effects were examined. Five psychogeriatric patients treated by the authors are presented.
Results: The review of the literature highlighted the lack of studies on the use of clozapine in the elderly. Retrospective studies and case reports dominate. There is only one double-blind placebo-controlled study of six patients extant. Although efficacy seemed to parallel that in the younger age groups, the incidence of leukopenia, agranulocytosis, postural hypotension and confusion was greater in the elderly. Two of the five patients reported by the authors developed agranulocytosis, bringing the Australian experience of agranulocytosis in patients over 65 years of age to 4/55.
Conclusion: The risk/benefit ratio in the elderly is distinctly higher than found in the younger population. With specific reference to agranulocytosis alone, the frequently quoted risk of 1% for patients is likely to be 5–10 times higher in the over 65 population. Caution is advised when prescribing clozapine in the psychogeriatric population.
KaneJM.Clinical efficacy of clozapine in treatment-refractory schizophrenia. An overview. British Journal of Psychiatry1992; 17:41–45.
2.
MeltzerHY.Treatment of the neuroleptic non responsive schizophrenic patient. Schizophrenia Bulletin1992; 18:515–542.
3.
MeltzerHYColaPA.The pharmacoeconomics of clozapine: a review. Journal of Clinical Psychiatry1994; 9:161–165.
4.
KruppPBarnesP.Clozapine-associated agranulocytosis: risk and aetiology. British Journal of Psychiatry1992; 160:38–40.
5.
AlvirJMJJeffreyPHLiebermanASaffermanAZSchwimmerJLSchaafJA.Clozapine-induced agranulocytosis: incidence and risk factor in the United States. New England Journal of Medicine1993; 329:162–167.
6.
LiebermanJASaffermanAZ.Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatry Quarterly1993; 63:51–70.
7.
AmslerHATeerenhoviLBarthEHarjulaKVuopioV.Agranulocytosis in patients treated with clozapine. Study of the Finnish epidemic. Acta Psychiatrica Scandinavica1977; 56:241–248.
8.
LiebermanJAYunisJEgeaECanosaRTKaneJMYunisEJ.HLA-B38, DR4, DQW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry1990; 47:945–948.
9.
YunisJCorzoDSalazarMLiebermanJAHowardAYunisEJ.HLA Associations in clozapine-induced agranulocytosis. Blood1995; 86:1177–1183.
10.
NandelAGrossM.Agranulocytosis and phenothiazines. Diseases of the Nervous System1968; 29:32–36.
11.
PisciottaAV.Agranulocytosis—induced by phenothiazine derivatives. Journal of the American Medical Association1969; 208:1862–1868.
12.
HeimpelH.Drug-induced agranulocytosis. Medical Toxicology1988; 3:449–462.
13.
GersenSL.G-CSF and the management of clozapine-induced agranulocytosis. Journal of Clinical Psychiatry1994; 9:139–142.
14.
MendelowitzAJGersonSLAlvirJMJLibermanJA.Clozapine-induced agranulocytosis: risk factors, monitoring and management. CNS Drugs1995; 4:412–421.
15.
MatzRRickWOhDThompsonHGershonS.Clozapine: a potential antipsychotic agent without extrapyramidal manifestations. Current Therapeutic Research1974; 16:687–695.
16.
KaplanHISadockBJ.Clozapine: antipsychotic. In: Psychiatric drug treatment. Baltimore: Williams and Wilkins, 1993:91–97.
17.
KahnNFreemanAJuncosJLManningDWattsRL.Clozapine is beneficial for psychosis in Parkinson's disease. Neurology1991; 41:1699–1700.
18.
SzymanskiSJodyDLeipzigRMaziarSLiebermanJ.Anticholinergic delirium caused by retreatment with clozapine. American Journal of Psychiatry1991; 148:1752.
19.
PitnerJKMintzerJEPennypackerLCJacksonCW.Efficacy and adverse effects of clozapine in four elderly psychotic patients. Journal of Clinical Psychiatry1995; 56:180–185.
20.
HavingCMerseVHuenpelCDose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacy1989; 99:538–540.
21.
CertorrinoFBaldessariniRJFloodJGRelation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. American Journal of Psychiatry1995; 152:610–612.
22.
OberholzerAFHerdriksenCMonschAVSafety and effectiveness of low dose clozapine in psychogeriatric patients: preliminary study. International Psychogeriatrics1992; 4:187–195.
23.
ChengappaKNRBakerRWKreinbrookSBAdairD.Clozapine use in female geriatric patients with psychoses. Journal of Geriatric Psychiatry and Neurology1995; 8:12–15.
24.
SalzmanCVaccaroBLieffJWeinerA.Clozapine in older patients with psychosis and behavioural disruption. American Journal of Geriatric Psychiatry1995; 3:26–33.
25.
FrankenburgFRKalunianD.Clozapine in the elderly. Journal of Geriatric Psychiatry and Neurology1994; 7:129–132.
26.
WolkSIDouglasCJ.Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. Journal of Clinical Psychiatry1992; 53:373–376.
27.
WoltersECHurwitzTAMakEClozapine in the treatment of Parkinsonian patients with dopaminomimetic psychosis. Neurology1990; 40:832–834.
28.
GowllandRW.Troubled asylum. New Norfolk, Tasmania: Gowlland, 1981.
29.
MamusSWBurtonJDGroatJDSchulteDALobellMZanjanhiED.Ibuprofen-associated pure white cell aplasia. New England Journal of Medicine1986; 314:624–625.
30.
ListAFBeairdPHKlummetT.Ranitidine-induced granulocytopenia: recurrence with cimetidine administration. Annals of Internal Medicine1988; 108:566–567.
31.
JonesJK.Hepatotoxicity associated with phenothiazines. Psychopharmacology Bulletin1983; 19:24–27.
32.
StahlSM.Conventional neuroleptic drugs for schizophrenia and novel anti-psychotic agents. In: Essential psychopharmacology. Melbourne: Cambridge University Press, 1996:263–288.
33.
CarlssonA.Recent advances in the therapeutics of schizophrenia: is dopamine still relevant?European Neuropsychopharmacology1996; 6:67.
